menu search

DMAC / DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10th. DiaMedica will host a live conference call on Thursday, August 11th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference C Read More
Posted: Aug 4 2022, 08:12
Author Name: Business Wire
Views: 092174

DMAC News  

DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 16, 2023

DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Ch more_horizontal

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

By Business Wire
May 8, 2023

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing r more_horizontal

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 29, 2023

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and more_horizontal

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

By Business Wire
March 20, 2023

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing r more_horizontal

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

By Business Wire
March 13, 2023

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treat more_horizontal

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 11, 2022

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and more_horizontal

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

By Business Wire
August 4, 2022

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treat more_horizontal

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why

By Benzinga
July 7, 2022

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why

The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic st more_horizontal


Search within

Pages Search Results: